Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 18/20 | 0.66 |
| ▸ | S1PR3 | Q99500 | 5/20 | 0.66 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.46 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2298213 | 0.92 | S1PR1 (0.67) | S1PR1S1PR3S1PR4S1PR5ALDH1A1 | |
| SCHEMBL2302581 | 0.90 | S1PR1 (0.71) | S1PR1S1PR3S1PR4S1PR5ALDH1A1 | |
| SCHEMBL1489950 | 0.85 | S1PR1 (0.67) | S1PR1S1PR3S1PR4S1PR5 | |
| SCHEMBL2298296 | 0.84 | S1PR1 (0.54) | S1PR1S1PR3ALDH1A1GLARAB9A | |
| SCHEMBL2302624 | 0.84 | S1PR1 (0.57) | S1PR1S1PR3S1PR4S1PR5 | |
| SCHEMBL2301727 | 0.81 | S1PR1 (0.72) | S1PR1S1PR3S1PR4S1PR5ALDH1A1 | |
| SCHEMBL1968117 | 0.81 | S1PR1 (0.84) | S1PR1S1PR3S1PR4S1PR5 | |
| SCHEMBL1967666 | 0.80 | S1PR1 (0.81) | S1PR1S1PR3S1PR4S1PR5 | |
| SCHEMBL2297820 | 0.80 | S1PR1 (0.53) | S1PR1S1PR3ALDH1A1GLARAB9A | |
| SCHEMBL2297971 | 0.80 | S1PR1 (0.70) | S1PR1S1PR3S1PR4S1PR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102186847-A | novel 2-amido thiadiazole derivatives | ALMIRALL SA | 2011-09-14 | — | — | CN | disclosed |
| US-20110200557-A1 | NEW 2-AMIDOTHIADIAZOLE DERIVATIVES | ALMIRALL, S.A. (ES) | 2011-08-18 | — | — | US | disclosed |
| US-20110200557-A1 | NEW 2-AMIDOTHIADIAZOLE DERIVATIVES | ALMIRALL, S.A. (ES) | 2011-08-18 | — | — | US | disclosed |
| US-20110200557-A1 | NEW 2-AMIDOTHIADIAZOLE DERIVATIVES | ALMIRALL, S.A. (ES) | 2011-08-18 | — | — | US | disclosed |
| WO-2010043377-A1 | NEW 2-AMIDOTHIADIAZOLE DERIVATIVES | ALMIRALL, S.A. (ES) | 2010-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110200557-A1 | NEW 2-AMIDOTHIADIAZOLE DERIVATIVES | S1PR2, S1PR3, S1PR1 | S1PR1 3/4885S1PR3 2/4885S1PR4 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.